Cargando…
Neurosteroids as novel antidepressants and anxiolytics: GABA-A receptors and beyond
The recent FDA approval of the neurosteroid, brexanolone (allopregnanolone), as a treatment for women with postpartum depression, and successful trials of a related neuroactive steroid, SGE-217, for men and women with major depressive disorder offer the hope of a new era in treating mood and anxiety...
Autores principales: | Zorumski, Charles F., Paul, Steven M., Covey, Douglas F., Mennerick, Steven |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804800/ https://www.ncbi.nlm.nih.gov/pubmed/31649968 http://dx.doi.org/10.1016/j.ynstr.2019.100196 |
Ejemplares similares
-
PPAR and functional foods: Rationale for natural neurosteroid-based interventions for postpartum depression
por: Matrisciano, Francesco, et al.
Publicado: (2020) -
Composite contributions of cerebrospinal fluid GABAergic neurosteroids, neuropeptide Y and interleukin-6 to PTSD symptom severity in men with PTSD
por: Kim, Byung Kil, et al.
Publicado: (2020) -
Realising the therapeutic potential of neuroactive steroid modulators of the GABA(A) receptor
por: Belelli, Delia, et al.
Publicado: (2019) -
Allopregnanolone in premenstrual dysphoric disorder (PMDD): Evidence for dysregulated sensitivity to GABA-A receptor modulating neuroactive steroids across the menstrual cycle
por: Hantsoo, Liisa, et al.
Publicado: (2020) -
Allopregnanolone: From molecular pathophysiology to therapeutics. A historical perspective
por: Paul, Steven M, et al.
Publicado: (2020)